NCT04671056已完成1 期
A Single Center, Open-Label, Drug Interaction Study of MGL-3196 With Pioglitazone and to Assess Food Effect in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- AUC from the time of dosing of pioglitazone as affected by chronic dosing with MGL-3196 100 mg/day in healthy subjects
研究概览
简要总结
The purpose of this study is to determine whether the single-dose pharmacokinetics (AUC) of pioglitazone are affected by chronic dosing with MGL-3196 100 mg/day in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Must be willing and able to provide written informed consent
- •Healthy, non-smoking male or female between the ages of 19 and 55 years (inclusive)
- •Body weight > 50 kg and BMI between 18 and 32 kg/m2 (inclusive)
- •If female, is non-pregnant and non-lactating. For females of non-childbearing potential, must have undergone sterilization procedures (hysteroscopic sterilization, bilateral tubal ligation or bilateral salpingectomy, hysterectomy, bilateral oophorectomy) at least 6 months prior to first dosing. Or, is postmenopausal with amenorrhea for at least 1 year prior to first dosing as verified by follicle stimulating hormone (FSH) at screening
- •If female of childbearing potential, must use acceptable non-hormonal birth control (surgical sterilization of the partner, physical barrier method for at least 30 days prior to first dosing in addition to spermicide from the time of screening throughout study completion, non-hormonal intrauterine device for at least 3 months prior to first dosing, total abstinence from sexual intercourse for at least at least 3 months prior to first dosing and throughout study completion)
- •If male and non-vasectomized, must agree to use a condom with spermicide or abstain from sexual intercourse from the first dose of study drug until 14 days beyond the last dose of study drug. No restrictions required for vasectomized male provided his vasectomy has been performed 3 months or more prior to Day
- •A male who has been vasectomized less than 3 months prior to study start must follow the same procedure as a non-vasectomized male.
排除标准
- •Any clinically significant abnormal findings on physical examination, clinical laboratory tests or 12-lead ECG.
- •Evidence or history of clinically significant hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, renal, hepatic, neurological or psychiatric disease.
- •Current or recent (<6 months) hepatobiliary disease; or AST, ALT or direct bilirubin greater than the upper limit of reference range at screening. Repeat testing is allowed per site standard procedures.
- •Gilbert's syndrome.
- •Pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function that could interfere with the absorption, metabolism, and/or excretion of study drug (Cholecystectomy is allowed).
- •Abnormal screening ECG: including machine-read QTcF >450 msec in men and QTcF > 470 msec in women (confirmed by manual over read) or any rhythm other than normal sinus rhythm which is interpreted by the Investigator to be clinically significant.
- •History of sensitivity to a similar study drug, thyroid medication, or a history of important drug or other allergy (except for untreated, asymptomatic seasonal allergies at time of dosing) unless deemed not clinically significant by the Investigator.
- •Participation in another clinical trial of an investigational drug (or medical device) within the last 30 days prior to the Day 1, or who have been exposed to more than four new chemical entities within 12 months prior to Day 1.
研究组 & 干预措施
MGL-3196 100 mg tablet plus Pioglitazone 15 mg tablet
Experimental
MGL-3196 administered orally plus Pioglitazone administered orally on 2 separate days
干预措施: MGL-3196 (Drug)
MGL-3196 100 mg tablet plus Pioglitazone 15 mg tablet
Experimental
MGL-3196 administered orally plus Pioglitazone administered orally on 2 separate days
干预措施: Pioglitazone 15mg (Drug)
结局指标
主要结局
AUC from the time of dosing of pioglitazone as affected by chronic dosing with MGL-3196 100 mg/day in healthy subjects
时间窗: 17 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)Hepatic InsufficiencyNCT05093972Merck Sharp & Dohme LLC22
已完成
4 期
Safety and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric PatientsPainFeverNCT02583399Cumberland Pharmaceuticals30
已完成
1 期
A Single-Dose, Pharmacokinetic/Pharmacodynamic (PK/PD), & Safety Study of BIIB017 in Participants With Renal Impairment & Healthy VolunteersHealthyRenal InsufficiencyNCT01119781Biogen35
已完成
1 期
Drug Interaction Study of MGL-3196 With ClopidogrelHealthyNCT04671069Madrigal Pharmaceuticals, Inc.20
已完成
1 期
Study of GSK3511294 in Healthy Chinese ParticipantsAsthmaNCT05140200GlaxoSmithKline20